CONSTITUENT REPORT
Valencene
Valencene is a citrus-linked sesquiterpene hydrocarbon best known for its fresh orange character and for serving as a precursor to nootkatone. Public evidence is solid for identity, citrus biosynthesis, fragrance safety, and a growing preclinical literature around inflammatory and oxidative-stress pathways. That evidence is still mostly animal, cell, or in-silico work rather than human clinical proof, so AromaForge copy should frame valencene as a chemistry-rich aroma constituent with early biological research, not as a validated therapeutic.
Chemical identity and composition
PubChem identifies valencene as C15H24 with InChIKey QEBNYNLSCGVZOH-NFAWXSAZSA-N. Citrus literature describes valencene as a major orange-associated sesquiterpene made from farnesyl diphosphate by valencene synthase (Cstps1). In the local archive it appears as a trace odor-active constituent in sweet orange and as a sometimes much larger marker in cypriol or nagarmotha profiles.
Aroma and practical use
- Use the recorded orange-like, citrus, sweet, fresh, woody descriptors to explore a blend's scent character; perceived strength also depends on the other ingredients.
- Read the route, preparation and experimental context before using a study finding to choose an oil.
Reported benefits and effects
Findings retain their study context. An animal or laboratory result describes that experiment.
A 2022 in-vivo and in-silico paper reported that valencene reduced paw edema, leukocyte recruitment, MPO, IL-1beta, and TNF-alpha in mouse acute and chronic inflammation models.
Europe PMC's abstract describes inhibition across carrageenan, dextran, histamine, and arachidonic-acid inflammation models plus reduced granuloma weight in chronic inflammation.
This experimental finding does not establish benefit, dose or safety in people using this blend.
A 2023 in-vitro and in-vivo osteoarthritis study reported that valencene reduced ROS and inflammatory signaling while protecting cartilage-related markers in mouse chondrocytes and a DMM mouse model.
The abstract reports NRF2/HO-1/NQO1 activation, NF-kB and MAPK suppression, and reduced osteophyte, subchondral bone damage, and cartilage erosion in vivo.
This experimental finding does not establish benefit, dose or safety in people using this blend.
Citrus genetics work linked valencene biosynthesis to valencene synthase (Cstps1), helping explain why some mandarin hybrids are valencene-deficient.
The PubMed record describes valencene as a major citrus-oil sesquiterpene biosynthesized from farnesyl diphosphate by valencene synthase.
This reference does not establish a therapeutic result or a safe use level for a custom oil blend.
Use concerns and concentration limits
Sensitization concernNot flagged
Not flagged in the current model. This is not proof of absence or unrestricted safety.
Phototoxicity concernNot flagged
Not flagged in the current model. This is not proof of absence or unrestricted safety.
Oxidation concernNot flagged
Not flagged in the current model. This is not proof of absence or unrestricted safety.
Penetration enhancementNot flagged
Not flagged in the current model. This is not proof of absence or unrestricted safety.
No numeric constituent-specific use limit is available here. Missing is not an unrestricted-use clearance.
The published RIFM safety assessment states valencene was not expected to be genotoxic, was not phototoxic/photoallergenic based on UV spectra, and had no skin-sensitization concern at current declared use levels under the DST framework.
The source assessment applies to its specified exposure and preparation; this entry is not an unrestricted-use clearance.
No direct public citation is attached to this entry.
The same RIFM assessment flagged environmental review as relevant even though the material was concluded not to be PBT or vPvB under the IFRA environmental standards framework.
The source assessment applies to its specified exposure and preparation; this entry is not an unrestricted-use clearance.
No direct public citation is attached to this entry.
Human therapeutic evidence for isolated valencene was not verified in this pass, so anti-inflammatory or cartilage-protection claims should remain explicitly preclinical.
This reference does not establish a therapeutic result or a safe use level for a custom oil blend.
No direct public citation is attached to this entry.
Constituents it may interact with
These are research candidates recorded in the interaction matrix. They do not add a proven-amplification bonus to the score.
gamma-TerpineneAmplification candidate
Candidate in the research matrix. A coefficient alone does not establish amplification at the dose, route or goal of your blend; no proven amplification is inferred from this row.
in vitro mechanistic · antioxidant
No source citation attached.
Read gamma-Terpinene report →How the effects were investigated
suppression of inflammatory mediators including MPO, IL-1beta, and TNF-alpha in murine models
The 2022 Europe PMC abstract reports lower leukocyte recruitment, MPO, IL-1beta, and TNF-alpha after valencene treatment in pleurisy and peritonitis models.
This experimental finding does not establish benefit, dose or safety in people using this blend.
interaction with COX-2 and H1 receptor in docking models
The same 2022 paper reports favorable docking energy toward COX-2 and the histamine H1 receptor, which supports but does not prove target-level mechanism.
This experimental finding does not establish benefit, dose or safety in people using this blend.
activation of NRF2/HO-1/NQO1 with inhibition of NF-kB and MAPK signaling in chondrocyte and mouse OA models
The 2023 abstract describes antioxidative and anti-inflammatory pathway modulation in IL-1beta-stimulated chondrocytes and a DMM mouse osteoarthritis model.
This experimental finding does not establish benefit, dose or safety in people using this blend.
What this report cannot establish
- A reported constituent percentage does not establish an effective human therapeutic dose or the amount absorbed into the body.
- The presence of a constituent does not guarantee a clinical benefit, rash treatment or sleep improvement from a custom blend.
- An unflagged concern or missing use limit does not establish safety for ingestion, inhalation, skin exposure or a particular person.
- A candidate constituent interaction does not establish that two oils amplify one another at the selected proportions.
- Constituent descriptors alone do not establish a precise top, heart or base lifetime in a finished blend.
Known data gaps (6)
- This pass did not verify a human clinical trial on isolated valencene alone.
- Many efficacy-facing valencene papers are disease-model studies; those findings should remain preclinical and not be translated into treatment claims.
- No constituent-specific IFRA dermal maximum was verified here beyond the broader RIFM safety framing.
- No constituent-specific numeric dermal reference is available here.
- Some findings do not record an explicit exposure route; consult the linked study before applying them to a use.
- Interaction candidates lack an attached source citation and remain unqualified.